Surge in Contraband Weight Loss Drugs Trafficked from Paraguay to Brazil

Brazil is witnessing a dramatic surge in the trafficking of contraband weight loss and diabetes medications produced in neighboring Paraguay. According to official data obtained by InSight Crime, seizures made by Brazil’s Federal Revenue Service (RFB) in the first half of 2026 were three times higher than all of 2025. This unprecedented spike has pushed these pharmaceuticals into the top six most seized contraband goods in Brazil.

The RFB's initial seizure of such medications occurred around 2023, coinciding with the approval of Mounjaro, now the leading brand in Brazil. However, seizures began to surge significantly starting from January 2026. The rapid increase is attributed to social media-driven demand and organized crime networks capitalizing on the lucrative market.

These medications, including GLP-1 brands like Ozempic and Mounjaro along with their generic substitutes, are being diverted through existing contraband routes. Most seizures now occur in Paraná state, particularly along the Caipira Route leading to São Paulo. This route's strategic location facilitates easy distribution across Brazil or internationally.

In Paraguay, armed robberies targeting pharmacies, distributors, warehouses, and transport vehicles carrying generic Mounjaro have surged during 2026. Thieves are making off with up to $500,000 worth of product at a time based on resale values estimated by authorities. Similar incidents are also reported in Brazil, where the country's largest pharmacy chain is losing around $900,000 (R$5 million) per month due to thefts and misappropriation.

Alan Towersey, who oversees search and seizure operations for the RFB, described this trend as a "weird outlier" because it involves a new substance in an emerging market. The surge highlights the evolving nature of drug trafficking and the adaptability of criminal organizations in exploiting legal pharmaceutical production gaps.

This phenomenon underscores broader issues within regional supply chains and regulatory frameworks that fail to keep pace with rapidly growing consumer demand for weight loss medications. As these trends continue, authorities face significant challenges in curbing the flow of contraband drugs into Brazil while addressing the underlying economic drivers fueling this illicit trade.